Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

NCT05498597 is registered in ClinicalTrials.gov with Multitude Therapeutics Inc. as lead sponsor.

NCT NCT05498597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05498597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Lead sponsor
Multitude Therapeutics Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
January 25, 2023
Completion date
October 30, 2024
Enrollment
30 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced carcinoma, advanced solid tumor, endometrial adenocarcinoma, endometrial cancer, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, lung adenocarcinoma, malignant pleural mesothelioma, ovarian cancer, ovarian carcinoma, ovarian clear cell adenocarcinoma, ovarian clear cell carcinoma, ovarian endometrioid adenocarcinoma, ovarian epithelial cancer, ovarian mucinous adenocarcinoma, pancreatic ductal adenocarcinoma, triple negative breast cancer